Metabolomics Analysis of the Development of Sepsis and Potential Biomarkers of Sepsis-Induced Acute Kidney Injury

Table 3

Differential metabolic pathways (CT vs. LPS6). The results of enriched compounds after screening and metabolic pathway enrichment analysis (MPEA) between the CT and LPS6 groups are summarized in this table.

	Total in pathway	Expected	Hits	Raw P		Holm P	FDR	Impact	Enriched compounds
Biosynthesis of unsaturated fatty acids	42	1.2882	5	0.007835	4.8492	0.63462	0.28969	0	(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Arachidonic acid; Linoleic acid; Palmitic acid; Stearic acid
Pantothenate and CoA biosynthesis	15	0.46006	3	0.009458	4.6609	0.75666	0.28969	0.07692	Beta-alanine; L-Cysteine; Uracil
Glyoxylate and dicarboxylate metabolism	16	0.49073	3	0.011394	4.4747	0.90014	0.28969	0.16666	Glyceric acid; Glycolic acid; Isocitric acid
Aminoacyl-tRNA biosynthesis	67	2.0549	6	0.014306	4.2471	1	0.28969	0.12498	L-Arginine; L-Cysteine; L-Histidine; L-Methionine; L-Proline; L-Tryptophan
Citrate cycle (TCA cycle)	20	0.61341	3	0.021295	3.8493	1	0.30896	0.10345	Fumaric acid; Isocitric acid; Oxoglutaric acid
Taurine and hypotaurine metabolism	8	0.24536	2	0.022886	3.7772	1	0.30896	0.5	L-Cysteine; Taurine
Arginine and proline metabolism	44	1.3495	4	0.042713	3.1532	1	0.49425	0.18368	Citrulline; Fumaric acid; L-Arginine; L-Proline

Holm: Holm-Bonferroni method; FDR: false discovery rate.